A potential mechanism for ADC-induced neutropenia: Role of neutrophils in their own demise

Molecular Cancer Therapeutics

Volumn 16, Issue 9, 2017, Pages 1866-1876

  Zhao, Hui ^a   Gulesserian, Sara ^a   Malinao, Maria Christina ^a   Ganesan, Sathish Kumar ^a   Song, James ^a   Chang, Mi Sook ^a   Williams, Melissa M ^a   Zeng, Zhilan ^a   Mattie, Michael ^a   Mendelsohn, Brian A ^a   Stover, David R ^a   Doñate, Fernando ^a  

^a Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; CITRULLINE; FC RECEPTOR; MONOMETHYL AURISTATIN F; SERINE PROTEINASE; UNCLASSIFIED DRUG; VALINE; VEDOTIN; ANTIBODY CONJUGATE; BIOLOGICAL MARKER;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL DIFFERENTIATION ASSAY; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CONDITIONED MEDIUM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; GIEMSA STAIN; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LEUKOCYTE FUNCTION; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN MICROARRAY; SENSITIVITY ANALYSIS; ANIMAL; BLOOD; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; IMMUNOPHENOTYPING; METABOLISM; MOUSE; MYELOPOIESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; MICE; MYELOPOIESIS; NEUTROPENIA; NEUTROPHILS; PINOCYTOSIS; RECEPTORS, IGG; SERINE PROTEASES;

EID: 85029426254     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-17-0133     Document Type: Article

References (34)

1. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013;76:248–62.
2. de Goeij BE, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016;40:14–23.
3. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778–84.
4. Pan LY, Salas-Solano O, Valliere-Douglass JF. Conformation and dynamics of interchain cysteine-linked antibody-drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry. Anal Chem 2014;86: 2657–64.
5. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016;8: 659–71.
6. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30: 2183–9.
7. Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, et al. The discovery and preclinical development of ASG-5ME, an antibody drug conjugate targeting SLC44A4 positive epithelial tumors including pancreatic and prostate cancer. Mol Cancer Ther 2016;15:2679–87.
8. Gudas JM, An Z, Morrison RK, Duniho SM, Moser R, Smith L, et al. ASG-5ME: A novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers. American Society of Clinical Oncology; 2010 June 4–8; Abstract No. 230.
9. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, et al. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs 2016;34:319–28.
10. Hinrichs MJ, Dixit R. Antibody drug conjugates: nonclinical safety considerations. AAPS J 2015;17:1055–64.
11. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114–24.
12. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008;14:6171–80.
13. Fathi AT, Borate U, DeAngelo DJ, O'Brien MM, Trippett T, Shah BD, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in adults with relapsed or refractory B-lineage acute leukemia (B-ALL) and highly aggressive lymphoma. Blood 2015;126:1328.
14. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014;32:1246–57.
15. Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol 2017;19:965–75.
16. Thompson JA, Motzer R, Molina AM, Choueiri TK, Heath EI, Kollmannsberger CK, et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J Clin Oncol 2015;33:15.
17. Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs 2017;35:315–23.
18. Donate F, Raitano A, Morrison K, An Z, Capo L, Avina H, et al. AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res 2016;22:1989–99.
19. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol 2010;31: 318–24.
20. Bekkering S, Torenma R. Another look at the life of neutrophil. World J Hematol 2013;2:15.
21. Pham CT. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 2006;6:541–50.
22. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013;13:159–75.
23. Lahoz-Beneytez J, Elemans M, Zhang Y, Ahmed R, Salam A, Block M, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood 2016;127: 3431–8.
24. Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C, et al. Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Reports 2015;4:282–96.
25. Chin JY, Kuan JY, Lonkar PS, Krause DS, Seidman MM, Peterson KR, et al. Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. Proc Natl Acad Sci U S A 2008;105:13514–9.
26. Zhao H, Gulesserian S, Ganesan S, Ou J, Morrison K, Zeng Z, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC induced thrombocytopenia. Mol Cancer Ther 2017;16:1877–86.
27. Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 2015;21: 123–33.
28. Wang JT, Teasdale RD, Liebl D. Macropinosome quantitation assay. MethodsX 2014;1:36–41.
29. Bournazos S, Ravetch JV. Fcgamma receptor pathways during active and passive immunization. Immunol Rev 2015;268:88–103.
30. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, et al. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991;78:885–9.
31. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540–7.
32. Catlin SN, Busque L, Gale RE, Guttorp P, Abkowitz JL. The replication rate of human hematopoietic stem cells in vivo. Blood 2011;117: 4460–6.
33. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013;218:1402–10.
34. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011;71:2411–6.